Lamy Patrick — SEC Form 4 filings
SEC reporting owner CIK 1961273. 15 Form 4 filings on record with FilingPulse; latest filed 2025-12-09.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-06-13 to 2025-12-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 16 legs across 12 filings — 30,288 shares, $1,456,364 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 5,000 shares @ $57.03 ($285,150) in Akero Therapeutics, Inc., filed 2025-01-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) | See Remarks | 15 | — | 16 legs · 30,288 sh · $1,456,364 | 25 |
Form 4 filings — Lamy Patrick
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 3,059 · Disposition to issuer (D): 26,832 · Disposition to issuer (D): 3,421 (derivative) · Disposition to issuer (D): 382 (derivative) · Disposition to issuer (D): 11,096 (derivative) · Disposition to issuer (D): 48,679 (derivative) · +2 more | EDGAR |
| 2025-07-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,000 @ $52.88 | EDGAR |
| 2025-07-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 193 @ $23.87 | EDGAR |
| 2025-06-20 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 2,000 @ $19.87 · Sale (S): 1,500 @ $53.82 · Sale (S): 500 @ $55.09 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 875 @ $54.59 | EDGAR |
| 2025-06-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 919 @ $54.00 | EDGAR |
| 2025-06-04 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 4,000 @ $19.87 · Sale (S): 600 @ $49.40 · Sale (S): 3,300 @ $50.46 · Sale (S): 100 @ $51.04 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 4,000 @ $44.37 · Sale (S): 4,000 @ $50 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 8,000 @ $19.87 · Sale (S): 4,701 @ $42.31 · Sale (S): 3,299 @ $42.76 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 1,000 @ $19.87 · Sale (S): 1,000 @ $48.09 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 234 @ $19.69 · Option exercise (M): 4,000 @ $19.87 · Sale (S): 5,000 @ $57.03 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 17,400 @ $0 · Sale (S): 1,000 @ $29.13 · Grant/award (A): 52,100 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 925 @ $30.79 | EDGAR |
| 2024-07-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 221 @ $19.94 | EDGAR |
| 2024-06-13 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 569 @ $22.64 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1961273 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →